According to Future Market Insights research, during the projected period, the global retinal gene therapy market is expected to grow at a CAGR of 9.2%. The market value is projected to increase from US$ 97.3 Million in 2023 to US$ 235.4 Million by 2033. The retinal gene therapy market was valued at US$ 89.9 Million at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 8.2% in 2023.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 89.9 Million |
| Market Value 2023 | US$ 97.3 Million |
| Market Value 2023 | US$ 235.4 Million |
| CAGR 2023 to 2033 | 9.2% |
| Share of Top 5 Countries | 55.7% |
| Key Players | Gyroscope Therapeutics (Novartis); Applied Genetic Technologies Corporation (AGTC); Spark Therapeutics; Adverum Biotechnologies; REGENXBIO Inc.; Biogen Inc.; Nightstar Therapeutics; MeiraGTx Holdings plc; GenSight Biologics; RetroSense Therapeutics; Second Sight Medical Products; Oxford Biomedica; Hemera Biosciences; Adverio Pharmaceuticals |
Retinal gene therapy is a treatment approach that aims to restore or replace the faulty or missing genes that cause inherited retinal diseases. Inherited retinal diseases like Retinitis Pigmentosa or Leber Congenital Amaurosis occur due to a genetic mutation that leads to the degeneration of photoreceptor cells in the retina, ultimately leading to vision loss or blindness.
Retinal gene therapy is a promising approach as it has the potential to provide a one-time treatment that could help patients with inherited retinal diseases to maintain or restore their vision. However, this treatment is still in the early stages of development and is not yet available as a standard treatment.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales of the retinal gene therapy grew at a CAGR of 7.7% between 2017 and 2022. The global market for retinal gene therapy contributes around 1.3% to the US$ 7.0 Billion gene therapy market in 2022.
The prevalence of inherited retinal diseases like Retinitis pigmentosa, Leber Congenital Amaurosis, and Choroideremia is increasing globally. This rise in the prevalence of these diseases is driving demand for new treatment options.
There is currently no cure for inherited retinal diseases. Existing treatments focus mainly on slowing disease progression, but they do not halt or reverse the damage already done. Retinal gene therapy has the potential to offer a once-in-a-lifetime cure or long-term solution for these debilitating diseases. As such, this significant unmet need is a key driver of continued development and commercialization efforts.
Significant advancements in surgical methods required for delivering altered genes to the retinal tissue have been made over the last two decades, which has facilitated the development of novel and revolutionary treatment approaches.
Owing to such factors, FMI projects the global market to grow over a CAGR of 9.2% through the forecast years.
The technological advancements in gene editing, viral vector development and delivery systems are enabling the development of more efficient and safe gene-based therapies. This has led to a surge in research and development activities aimed at exploring the potential of gene therapies for inherited retinal diseases.
Viral vectors, which are used to deliver genes into target cells, are key to gene therapy. The development of safer and more efficient viral vectors has been a major area of focus for gene therapy. For example, Adeno-associated virus (AAV) vectors have become the most commonly used viral delivery system for genetic therapies in humans.
Governments and private entities worldwide are increasingly investing in gene therapies for inherited diseases, including retinal disease. This funding increase has encouraged continued research and development, accelerating the development of gene therapies while providing financial support for clinical trials and commercialization efforts.
Principal Consultant
The probable obstruction to growth is affordability, as the cost associated with multiple dosages is one of the major concerns for patients and caregivers, as it would involve high costs and reimbursement procedures.
There remains regulatory uncertainty around reimbursement and market access for gene therapy products which also hinders growth, with potential regulatory challenges associated with gene therapies, affordability, access by health systems, and access to specialized care providers affecting the commercial uptake.
Retinal gene therapy being an early-phase developmental technology, the development process involves significant research and development costs, which require immense investments of time, money and resources.
The number of potential patients with inherited retinal diseases is limited, meaning the market size for these treatments is small. Also, awareness among healthcare professionals regarding this therapy is still limited in several low- to middle-income economic countries.
Inherently there are concerns surrounding gene therapy safety even after approval whereby follow up must take place due to potential side effects that may emerge.
Overall, these factors are capable of restraining the expansion of the market in the future as well.
The USA contributed the most in the North America and made a profitable market, holding about 34.2% in the global market by the end of year 2022.
Retinal gene therapy research in the USA is being conducted by many renowned research institutions and companies, which have made significant progress in the field over the last decade. These technological advancements have given the USA market a leading edge in Retinal gene therapy development.
Likewise, the USA government also provides significant funding towards research and development in the area of gene therapy, with a major portion of this going towards Retinal gene therapy.
Germany is one of the leading countries in Europe, with a significant growth rate of 7.5% over the forecast period.
Germany, together with the United Kingdom and France, has the highest incidence of age-related macular degeneration (AMD)-related blindness and also has a large patient pool inflicted with inherited retinal diseases. This patient pool is likely to create demands for gene therapies for the treatment of their visual abnormalities, consequently, this may provide companies to have a sizeable and established market for their products.
China is projected to be the most attractive market in the East Asia market, accounting for the global market share of around 6.5% in 2022.
With significant advances in gene therapy manufacturing technology, China is taking advantage of its affordable domestic manufacturing of gene therapy.
Many Chinese domestic companies are research and development focused on the development of gene therapies for inherited retinal diseases in the country. The Chinese government offers significant support to life science research, development, and production, which has led to a surge in domestic research and development within the country.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Stargardt disease accounted for the dominant share of 32.8% in the global market in 2022 and expected to expand at a CAGR of 9.7% throughout the forecast period.
The growing prevalence of Stargardt disease globally, particularly in developed economies, has created high demand for retinal gene therapy worldwide. The potential to restore visual function in patients with inherited retinal diseases like Stargardt disease has led to a surge in research and development in the area, with many companies working on retinal gene therapy to help address the high unmet demand for innovative treatments.
Hospitals held the significant share in the global market as a distribution channel with holding about 43.6% of the overall market by the end of 2022.
Retinal gene therapy is a highly technical procedure and requires specialization and expertise in delivering the therapy, making hospitals with specialized care facilities a natural fit as the leading end-users of the therapy.
Hospitals have the advantage of direct patient access which can be crucial for high-end gene therapies where patients require hospitalization to deliver the treatment. Retinal gene therapy could require such specialized inpatient care before the patient is transitioned to at-home care.
Due to the high market concentration and sub-segmented market, companies are relying on research and development of novel therapies to deliver the treatment more effectively and efficiently. Companies such as Janssen Biotech, have currently entered the market and continue to invest heavily in research and development.
Overall, research and development, strategic collaborations, regulatory approvals, and international expansion remain top priorities for companies looking to increase their market share in the retinal gene therapy industry, with competition driving innovation, and making the therapy available and more cost-effective on a wider scale.
For instance:
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the retinal gene therapy market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, GCC Countries, Northern Africa |
| Key Segments Covered | Indication, End User, and Region |
| Key Companies Profiled | Gyroscope Therapeutics (Novartis); Applied Genetic Technologies Corporation (AGTC); Spark Therapeutics; Adverum Biotechnologies; REGENXBIO Inc.; Biogen Inc.; Nightstar Therapeutics; MeiraGTx Holdings plc; GenSight Biologics; RetroSense Therapeutics; Second Sight Medical Products; Oxford Biomedica; Hemera Biosciences; Adverio Pharmaceuticals |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is valued at US$ 97.3 million in 2023.
The market is estimated to reach US$ 235.4 million by 2033.
The United States, Japan, and China dominate the global market.
The market is forecast to register a CAGR of 9.2% through 2033.
The technological advancements in gene editing, viral vector development, and delivery systems enable the development of more efficient gene-based therapies.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. FMI Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions/Exclusions
3. Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Disease Epidemiology by Region
4.2. Treatment Adoption / Usage Analysis, by Region
4.3. Patient Treatment Regime
4.4. Regulatory Scenario
4.5. PESTEL Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Healthcare Expenditure Outlook
5.1.2. Global Pharmaceutical Industry Outlook
5.1.3. Global Gene Therapy Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Prevalence Rate of Genetic Disorders Like Retinitis Pigmentosa and Leber Congenital Amaurosis
5.2.2. Increasing Awareness Among Physicians and Patients About the Benefits of Gene Therapy for Retinal Diseases
5.2.3. Technological Advancements in Gene Delivery Platforms Like Viral Vectors or Gene Editing Tools
5.2.4. Regulatory Approvals and Increasing Research & Development Activities to Advance Gene Therapy Treatments for Various Diseases
5.2.5. Developing Healthcare Infrastructure in Emerging Countries
5.2.6. Rising Collaborations and Partnerships Among Research Organizations to Develop Gene Therapies
5.2.7. Increasing Investments in the Gene Therapy Market by Pharmaceutical Companies and Government Bodies
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Mn) Analysis 2017 – 2022 and Forecast, 2023 – 2033
6.1. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
6.2. Historical Market Value (US$ Mn) Analysis, 2017 – 2022
6.3. Current and Future Market Value (US$ Mn) Projections, 2023 – 2033
6.3.1. Y-o-Y Growth Trend Analysis
6.3.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2017 – 2022 and Forecast 2023 – 2033, By Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Indication, 2017 – 2022
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2023 – 2033
7.3.1. Leber Congenital Amaurosis (LCA)
7.3.2. Stargardt Disease
7.3.3. Choroideremia
7.3.4. X-linked Retinitis Pigmentosa (RP)
7.3.5. Others
7.4. Market Attractiveness Analysis By Indication
8. Global Market Analysis 2017 – 2022 and Forecast 2023 – 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By End User, 2017 – 2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2023 – 2033
8.3.1. Hospitals
8.3.2. Academic & Research Institutes
8.3.3. Ophthalmic Clinics
8.3.4. Others
8.4. Market Attractiveness Analysis By End User
9. Global Market Analysis 2017 – 2022 and Forecast 2023 to 2033, by Region
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis, By Region, 2017 – 2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023 – 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2017 – 2022 and Forecast 2023 to 2033
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
10.3.1. By Country
10.3.1.1. USA
10.3.1.2. Canada
10.3.2. By Indication
10.3.3. By End User
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Indication
10.4.3. By End User
10.5. Market Trends
10.6. Market Drivers & Restraints – Impact Analysis
10.7. Country Level Analysis & Forecast
10.7.1. USA Market
10.7.1.1. Introduction
10.7.1.2. Market Analysis and Forecast by Market Taxonomy
10.7.1.2.1. By Indication
10.7.1.2.2. By End User
10.7.2. Canada Market
10.7.2.1. Introduction
10.7.2.2. Market Analysis and Forecast by Market Taxonomy
10.7.2.2.1. By Indication
10.7.2.2.2. By End User
11. Latin America Market Analysis 2017 – 2022 and Forecast 2023 to 2033
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
11.3.1. By Country
11.3.1.1. Brazil
11.3.1.2. Mexico
11.3.1.3. Argentina
11.3.1.4. Rest of LATAM
11.3.2. By Indication
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Indication
11.4.3. By End User
11.5. Market Trends
11.6. Market Drivers & Restraints – Impact Analysis
11.7. Country Level Analysis & Forecast
11.7.1. Brazil Market
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast by Market Taxonomy
11.7.1.2.1. By Indication
11.7.1.2.2. By End User
11.7.2. Mexico Market
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast by Market Taxonomy
11.7.2.2.1. By Indication
11.7.2.2.2. By End User
11.7.3. Argentina Market
11.7.3.1. Introduction
11.7.3.2. Market Analysis and Forecast by Market Taxonomy
11.7.3.2.1. By Indication
11.7.3.2.2. By End User
12. Europe Market Analysis 2017 – 2022 and Forecast 2023 to 2033
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
12.3.1. By Country
12.3.1.1. UK
12.3.1.2. Germany
12.3.1.3. France
12.3.1.4. Italy
12.3.1.5. Spain
12.3.1.6. BENELUX
12.3.1.7. Russia
12.3.1.8. Rest of Europe
12.3.2. By Indication
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Indication
12.4.3. By End User
12.5. Market Trends
12.6. Market Drivers & Restraints – Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. UK Market
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast by Market Taxonomy
12.7.1.2.1. By Indication
12.7.1.2.2. By End User
12.7.2. Germany Market
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast by Market Taxonomy
12.7.2.2.1. By Indication
12.7.2.2.2. By End User
12.7.3. France Market
12.7.3.1. Introduction
12.7.3.2. Market Analysis and Forecast by Market Taxonomy
12.7.3.2.1. By Indication
12.7.3.2.2. By End User
12.7.4. Italy Market
12.7.4.1. Introduction
12.7.4.2. Market Analysis and Forecast by Market Taxonomy
12.7.4.2.1. By Indication
12.7.4.2.2. By End User
12.7.5. Spain Market
12.7.5.1. Introduction
12.7.5.2. Market Analysis and Forecast by Market Taxonomy
12.7.5.2.1. By Indication
12.7.5.2.2. By End User
12.7.6. BENELUX Market
12.7.6.1. Introduction
12.7.6.2. Market Analysis and Forecast by Market Taxonomy
12.7.6.2.1. By Indication
12.7.6.2.2. By End User
12.7.7. Russia Market
12.7.7.1. Introduction
12.7.7.2. Market Analysis and Forecast by Market Taxonomy
12.7.7.2.1. By Indication
12.7.7.2.2. By End User
13. East Asia Market Analysis 2017 – 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
13.3.1. By Country
13.3.1.1. China
13.3.1.2. Japan
13.3.1.3. South Korea
13.3.2. By Indication
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Indication
13.4.3. By End User
13.5. Market Trends
13.6. Market Drivers & Restraints – Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. China Market
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Indication
13.7.1.2.2. By End User
13.7.2. Japan Market
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Indication
13.7.2.2.2. By End User
13.7.3. South Korea Market
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast by Market Taxonomy
13.7.3.2.1. By Indication
13.7.3.2.2. By End User
14. South Asia Market Analysis 2017 – 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Indonesia
14.3.1.3. Thailand
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Indication
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Indication
14.4.3. By End User
14.5. Market Trends
14.6. Market Drivers & Restraints – Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. India Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Indication
14.7.1.2.2. By End User
14.7.2. Indonesia Market
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Indication
14.7.2.2.2. By End User
14.7.3. Thailand Market
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Indication
14.7.3.2.2. By End User
14.7.4. Malaysia Market
14.7.4.1. Introduction
14.7.4.2. Market Analysis and Forecast by Market Taxonomy
14.7.4.2.1. By Indication
14.7.4.2.2. By End User
15. Oceania Market Analysis 2017 – 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
15.3.1. By Country
15.3.1.1. Australia
15.3.1.2. New Zealand
15.3.2. By Indication
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Indication
15.4.3. By End User
15.5. Market Trends
15.6. Market Drivers & Restraints – Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Australia Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Indication
15.7.1.2.2. By End User
15.7.2. New Zealand Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Indication
15.7.2.2.2. By End User
16. Middle East & Africa Market Analysis 2017 – 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017 – 2022
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2023 – 2033
16.3.1. By Country
16.3.1.1. GCC Countries
16.3.1.2. Türkiye
16.3.1.3. South Africa
16.3.1.4. Northern Africa
16.3.1.5. Rest of Middle East and Africa
16.3.2. By Indication
16.3.3. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Indication
16.4.3. By End User
16.5. Market Trends
16.6. Market Drivers & Restraints – Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. GCC Countries Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Indication
16.7.1.2.2. By End User
16.7.2. Türkiye Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Indication
16.7.2.2.2. By End User
16.7.3. South Africa Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Indication
16.7.3.2.2. By End User
16.7.4. Northern Africa Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Indication
16.7.4.2.2. By End User
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies (Maternity Care Products)
17.2. Market Share Analysis of Top Players
17.3. Market Concentration
18. Competition Analysis
18.1. Competition Dashboard
18.2. Branding and Promotional Strategies, By key Players
18.3. Key Development Analysis
18.4. Competition Deep Dive
18.4.1. Gyroscope Therapeutics (Novartis)
18.4.1.1. Overview
18.4.1.2. Product Portfolio
18.4.1.3. Key Financials
18.4.1.4. SWOT Analysis
18.4.1.5. Key Developments
18.4.1.6. Sales Footprint
18.4.1.7. Strategy Overview
18.4.1.7.1. Marketing Strategy
18.4.1.7.2. Product Strategy
18.4.1.7.3. Channel Strategy
18.4.2. Applied Genetic Technologies Corporation (AGTC)
18.4.2.1. Overview
18.4.2.2. Product Portfolio
18.4.2.3. Key Financials
18.4.2.4. SWOT Analysis
18.4.2.5. Key Developments
18.4.2.6. Sales Footprint
18.4.2.7. Strategy Overview
18.4.2.7.1. Marketing Strategy
18.4.2.7.2. Product Strategy
18.4.2.7.3. Channel Strategy
18.4.3. Spark Therapeutics
18.4.3.1. Overview
18.4.3.2. Product Portfolio
18.4.3.3. Key Financials
18.4.3.4. SWOT Analysis
18.4.3.5. Key Developments
18.4.3.6. Sales Footprint
18.4.3.7. Strategy Overview
18.4.3.7.1. Marketing Strategy
18.4.3.7.2. Product Strategy
18.4.3.7.3. Channel Strategy
18.4.4. Adverum Biotechnologies
18.4.4.1. Overview
18.4.4.2. Product Portfolio
18.4.4.3. Key Financials
18.4.4.4. SWOT Analysis
18.4.4.5. Key Developments
18.4.4.6. Sales Footprint
18.4.4.7. Strategy Overview
18.4.4.7.1. Marketing Strategy
18.4.4.7.2. Product Strategy
18.4.4.7.3. Channel Strategy
18.4.5. REGENXBIO Inc.
18.4.5.1. Overview
18.4.5.2. Product Portfolio
18.4.5.3. Key Financials
18.4.5.4. SWOT Analysis
18.4.5.5. Key Developments
18.4.5.6. Sales Footprint
18.4.5.7. Strategy Overview
18.4.5.7.1. Marketing Strategy
18.4.5.7.2. Product Strategy
18.4.5.7.3. Channel Strategy
18.4.6. Biogen Inc.
18.4.6.1. Overview
18.4.6.2. Product Portfolio
18.4.6.3. Key Financials
18.4.6.4. SWOT Analysis
18.4.6.5. Key Developments
18.4.6.6. Sales Footprint
18.4.6.7. Strategy Overview
18.4.6.7.1. Marketing Strategy
18.4.6.7.2. Product Strategy
18.4.6.7.3. Channel Strategy
18.4.7. Nightstar Therapeutics
18.4.7.1. Overview
18.4.7.2. Product Portfolio
18.4.7.3. Key Financials
18.4.7.4. SWOT Analysis
18.4.7.5. Key Developments
18.4.7.6. Sales Footprint
18.4.7.7. Strategy Overview
18.4.7.7.1. Marketing Strategy
18.4.7.7.2. Product Strategy
18.4.7.7.3. Channel Strategy
18.4.8. MeiraGTx Holdings plc
18.4.8.1. Overview
18.4.8.2. Product Portfolio
18.4.8.3. Key Financials
18.4.8.4. SWOT Analysis
18.4.8.5. Key Developments
18.4.8.6. Sales Footprint
18.4.8.7. Strategy Overview
18.4.8.7.1. Marketing Strategy
18.4.8.7.2. Product Strategy
18.4.8.7.3. Channel Strategy
18.4.9. GenSight Biologics
18.4.9.1. Overview
18.4.9.2. Product Portfolio
18.4.9.3. Key Financials
18.4.9.4. SWOT Analysis
18.4.9.5. Key Developments
18.4.9.6. Sales Footprint
18.4.9.7. Strategy Overview
18.4.9.7.1. Marketing Strategy
18.4.9.7.2. Product Strategy
18.4.9.7.3. Channel Strategy
18.4.10. RetroSense Therapeutics
18.4.10.1. Overview
18.4.10.2. Product Portfolio
18.4.10.3. Key Financials
18.4.10.4. SWOT Analysis
18.4.10.5. Key Developments
18.4.10.6. Sales Footprint
18.4.10.7. Strategy Overview
18.4.10.7.1. Marketing Strategy
18.4.10.7.2. Product Strategy
18.4.10.7.3. Channel Strategy
18.4.11. Second Sight Medical Products
18.4.11.1. Overview
18.4.11.2. Product Portfolio
18.4.11.3. Key Financials
18.4.11.4. SWOT Analysis
18.4.11.5. Key Developments
18.4.11.6. Sales Footprint
18.4.11.7. Strategy Overview
18.4.11.7.1. Marketing Strategy
18.4.11.7.2. Product Strategy
18.4.11.7.3. Channel Strategy
18.4.12. Oxford Biomedica
18.4.12.1. Overview
18.4.12.2. Product Portfolio
18.4.12.3. Key Financials
18.4.12.4. SWOT Analysis
18.4.12.5. Key Developments
18.4.12.6. Sales Footprint
18.4.12.7. Strategy Overview
18.4.12.7.1. Marketing Strategy
18.4.12.7.2. Product Strategy
18.4.12.7.3. Channel Strategy
18.4.13. Hemera Biosciences
18.4.13.1. Overview
18.4.13.2. Product Portfolio
18.4.13.3. Key Financials
18.4.13.4. SWOT Analysis
18.4.13.5. Key Developments
18.4.13.6. Sales Footprint
18.4.13.7. Strategy Overview
18.4.13.7.1. Marketing Strategy
18.4.13.7.2. Product Strategy
18.4.13.7.3. Channel Strategy
18.4.14. Adverio Pharmaceuticals
18.4.14.1. Overview
18.4.14.2. Product Portfolio
18.4.14.3. Key Financials
18.4.14.4. SWOT Analysis
18.4.14.5. Key Developments
18.4.14.6. Sales Footprint
18.4.14.7. Strategy Overview
18.4.14.7.1. Marketing Strategy
18.4.14.7.2. Product Strategy
18.4.14.7.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Retinal Gene Therapy Market
